We are committed to finding a cure for WM.

Medical/Research Updates

1 2 3 11

BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for the treatment of patients with Waldenström’s… Continue reading

2019 WMFC Educational Forum Presentation – Dr. Chen

Dr. Christine Chen from the Princess Margaret Cancer Centre presenting on ” Navigating Treatment Options for Waldenstrom’s Macroglobulinemia in Canada” at the 2019 WMFC Educational Forum Toronto – April 2019

1 2 3 11